Karyopharm Therapeutics Inc. Net Change in Cash
Karyopharm Therapeutics Inc. (KPTI) reported Net Change in Cash of -$5.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $30.28M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$23.69M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$21.80M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$51.34M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$1.92M, a 119.99% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $9.62M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$83.69M.
- Karyopharm Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$60.56M, a 155.91% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.59M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $30.28M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$1.92M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | -$24.79M 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | -$23.74M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$23.69M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $9.62M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $19.98M 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $31.92M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$21.80M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$83.69M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | -$92.30M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | -$55.04M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$51.34M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$60.56M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$124.39M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$113.42M 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | -$42.54M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $108.32M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $51.32M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $53.59M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $883.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$41.57M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | -$46.58M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | -$24.96M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $73.26M 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $11.95M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $49.98M 10-Q · filed 2020-11-02 | |||
| 2019-06-30 | -$42.48M 10-Q · filed 2020-08-04 | |||
| 2019-03-31 | -$34.52M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $49.25M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $32.83M 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | $50.12M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | -$31.70M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $19.34M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $4.80M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $5.72M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | -$24.09M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$8.70M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |